HIV
GSK unveils strong showing for twin-drug HIV treatment
February 14, 2017Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, HIV, Tivicay
GlaxoSmithKline has announced strong Phase 3 findings for its own Tivicay (dolutegravir) as part of a twin-drug regimen with J&J’s …
New research reverses HIV-related immune suppression
December 21, 2016Research and Development HIV, UNC School of Medicine
The UNC School of Medicine has released new research which appears to offer a new approach to HIV treatment which …
Collaboration on new therapeutic vaccine for HIV shows promise
November 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson
Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …
Kymab demonstrates promising research for HIV vaccine development
September 9, 2016Medical Communications, Research and Development HIV, Vaccine, kymab
Cambridge-based antibodies-to-medicines company Kymab has announced publication of research testing the first step in the effort to develop effective vaccines …
Gilead gets EU approval for HIV-prevention treatment Truvada
August 23, 2016Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention
Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …
ViiV Healthcare launches Phase III trial for combo HIV treatment
August 16, 2016Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III
The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …
Gilead to work with Genmab on HIV targeting technology
August 12, 2016Medical Communications, Research and Development, Sales and Marketing Genmab, Gilead, HIV, duobody
Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform …
EU recommends PrEP in Gilead’s HIV prevention treatment
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention
Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …
EU grants approval for Gilead’s HIV treatment Descovy
April 26, 2016Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf
Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …
IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition
April 11, 2016Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV
German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …
HIV successfully overcomes CRISPR gene-editing technology
April 8, 2016Research and Development HIV, crispr, failure, setback
Researchers using the CRISPR gene-editing technology have indicated that HIV can defeat efforts to cripple it, but have characterised it …
FDA approves Gilead’s latest HIV treatment
April 5, 2016Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy
Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …
Janssen-Cilag’s HIV treatment gets NHS backing
March 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial
Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV. The company said following the …
FDA bans clinical trial co-ordinator who faked patient samples and stole funds
March 22, 2016Manufacturing and Production, Medical Communications FDA, HIV, clinical trials, faked, forgery, mcquerry, prison
The US Food and Drug Administration has permanently banned a clinical trial co-ordinator who was found to have falsified patient …
FDA approves Gilead’s Odefsey for treatment of HIV-1 infection
March 2, 2016Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
